Clinical Trial Update: Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Ivonescimab plus short-course hypofractionated radiotherapy as second-line therapy for esophageal squamous cell carcinoma is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING